NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Meta Platforms, Inc. (“Meta” or the “Company”) (NASDAQ: META).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Meta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 15, 2025, ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving NeuroPace, Inc. and its officers or directors [1] Group 1: Company Performance - On May 27, 2025, NeuroPace announced the preliminary one-year results of the NAUTILUS study, which evaluated the safety and effectiveness of the RNS System for treating drug-resistant idiopathic generalized epilepsy (IGE) [3] - The study did not achieve statistical significance for its primary effectiveness endpoint, which aimed to demonstrate a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group [3] - Following the announcement, NeuroPace's stock price dropped by $5.02 per share, or 28.39%, closing at $12.66 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of NeuroPace to gather information regarding potential claims related to securities fraud [1] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Elevance Health, Inc. is facing a class action lawsuit due to alleged misleading statements and failure to disclose adverse facts regarding its business operations and financial guidance during the Class Period from April 18, 2024, to October 16, 2024 [1][4]. Financial Performance - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, which led to a stock price drop of $32.21, or 5.8%, closing at $520.93 per share [2]. - On October 17, 2024, Elevance reported third quarter 2024 financial results, missing EPS consensus estimates by 13.7% and lowering its EPS guidance for 2024 by 11.3%, resulting in a further stock price decline of $52.61, or 10.6%, to close at $444.35 per share [3]. Lawsuit Details - The class action complaint alleges that Elevance's management made materially false and misleading statements and failed to disclose significant adverse facts, including the higher costs associated with sicker patients remaining on Medicaid and inadequate reflection of these costs in financial guidance [4]. - Investors who purchased Elevance common stock during the Class Period have until July 11, 2025, to file a lead plaintiff motion in the lawsuit [5].

Core Viewpoint - West Pharmaceutical Services, Inc. is facing a class action lawsuit due to significant stock price decline following disappointing revenue and earnings forecasts, attributed to operational challenges and customer losses [2][3]. Group 1: Company Performance - On February 13, 2025, West issued disappointing revenue and earnings forecasts for 2025, citing Contract Manufacturing headwinds and the loss of two major continuous glucose monitoring customers [2]. - The company's SmartDose wearable injector devices are expected to be "margin dilutive" in 2025, prompting the need for steps to improve its economics [2]. - Following the announcement, West's stock price fell by $123.17, or 38.2%, closing at $199.11 per share [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that West made materially false and misleading statements throughout the class period, failing to disclose significant operational issues [3]. - Specific allegations include ongoing destocking across West's high-margin HVP portfolio and operational inefficiencies related to the SmartDose device, which was expected to be a high-margin growth product [3]. - The lawsuit claims that these margin pressures could lead to costly restructuring activities, including exiting contracts with long-standing customers in the continuous glucose monitoring sector [3].

Core Viewpoint - The article discusses a class action lawsuit against DoubleVerify Holdings, Inc. due to significant stock price declines following disappointing financial results and allegations regarding the effectiveness of its services [1][5]. Financial Performance - On May 7, 2024, DoubleVerify reported its Q1 2024 financial results, reducing its 2024 revenue guidance due to a pullback in customer advertising spending, resulting in a stock price drop of $11.79, or 38.6%, closing at $18.78 per share on May 8, 2024 [2]. - On February 27, 2025, the company announced lower-than-expected Q4 2024 sales and earnings, with a stock price decline of $7.83, or 36%, closing at $13.90 per share on February 28, 2025 [3]. Allegations and Lawsuit Details - The lawsuit alleges that DoubleVerify made materially false and misleading statements and failed to disclose adverse facts about its business, including: - Customers shifting ad spending to closed platforms where DoubleVerify's capabilities are limited [5]. - High costs and time required for developing technology for closed platforms [5]. - Competitors being better positioned to incorporate AI, impacting DoubleVerify's competitiveness [5]. - Systematic overbilling of customers for ad impressions served to bots [5]. - Misleading risk disclosures that characterized adverse facts as mere possibilities [5]. Class Action Participation - Investors who purchased DoubleVerify securities during the specified class period may file a lead plaintiff motion by July 21, 2025 [6].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] Financial Performance - Treace Medical lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to a range of $201 million to $211 million [3] - Following this announcement, Treace Medical's stock price fell by $6.95, nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [4] Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5]

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Bitfarms Ltd. ("Bitfarms" or the "Company") (NASDAQ: BITF) and certain officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-02630, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Bitfarms securities between March 21, 2023 and December 9, 2 ...

Core Viewpoint - A class action lawsuit has been filed against Red Cat Holdings, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its production capacity and contract value, leading to investor losses [1][4]. Group 1: Lawsuit Details - The Schall Law Firm has initiated a class action lawsuit against Red Cat Holdings, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - The lawsuit targets investors who purchased Red Cat's securities between March 18, 2022, and January 15, 2025, encouraging them to contact the firm before July 22, 2025 [2]. - The class has not yet been certified, meaning potential class members are not currently represented by an attorney [3]. Group 2: Allegations Against Red Cat - The complaint alleges that Red Cat Holdings overstated the production capacity of its Salt Lake City facility and the value of its Short Range Reconnaissance Program of Record Tranche 2 contract [4]. - These misleading statements are claimed to have caused material misrepresentation throughout the class period, resulting in damages to investors when the truth was revealed [4].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for the period between April 18, 2024, and October 16, 2024, due to financial disclosures that negatively impacted the company's stock price [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Financial Disclosures - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization for the second half of the year, leading to a stock price decline of $32.21 per share, or 5.8%, closing at $520.93 [4]. - On October 17, 2024, Elevance reported Q3 2024 financial results, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business. The EPS guidance for 2024 was lowered from $37.20 to $33.00, or 11.3% [5]. - Following the Q3 results announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [6].

Core Viewpoint - Avis Budget Group, Inc. is facing allegations of issuing materially false and misleading statements regarding its fleet rotation plan, which has led to significant financial implications for the company [1]. Group 1: Allegations and Financial Impact - The complaint alleges that Avis Budget implemented a plan to significantly accelerate its fleet rotation in Q4 2024 [1]. - This acceleration shortened the useful life of the majority of the company's vehicles in the Americas segment, reducing their recoverable value [1]. - As a result, Avis Budget is expected to recognize billions of dollars in impairment charges and incur substantial losses [1]. - The aforementioned actions are likely to have a significant negative impact on the company's financial results [1]. - Consequently, the financial and business prospects of Avis Budget were overstated, making the defendants' public statements materially false and misleading [1]. Group 2: Class Action Details - Shareholders who purchased shares of Avis Budget during the class period from February 16, 2024, to February 10, 2025, are encouraged to register for the class action [2]. - The deadline for shareholders to seek lead plaintiff status is June 24, 2025 [2]. - There is no cost or obligation for shareholders to participate in this case [2].